Dapsone
Aczone, Dapsone (dapsone) is a small molecule pharmaceutical. Dapsone was first approved as Dapsone on 1982-01-01. It is used to treat aids-related opportunistic infections, dermatitis herpetiformis, lepromatous leprosy, and relapsing polychondritis in the USA. It is known to target hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Aczone (generic drugs available since 1982-01-01)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 011503 dapsone 6% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2020-07-02 |
| 011504 dapsone 8.5% / niacinamide 4% | unapproved drug other | 2020-07-02 |
| aczone | New Drug Application | 2023-06-12 |
| dapsone | ANDA | 2024-01-31 |
| dapsone 6% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2019-05-10 |
| dapsone 6% / niacinamide 2% / tretinoin 0.025% | unapproved drug other | 2019-05-03 |
| dapsone 6% / niacinamide 4% | unapproved drug other | 2019-04-23 |
| dapsone 8.5% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2019-05-09 |
| dapsone 8.5% / niacinamide 2% / tretinoin 0.025% | unapproved drug other | 2019-05-02 |
| dapsone 8.5% / niacinamide 4% | unapproved drug other | 2019-04-23 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AX: Other anti-acne preparations for topical use in atc
— D10AX05: Dapsone
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04B: Drugs for treatment of lepra
— J04BA: Drugs for treatment of lepra
— J04BA02: Dapsone
— J04BA50: Dapsone and rifampicin
— J04BA51: Dapsone, rifampicin and clofazimine
HCPCS
No data
Clinical
Clinical Trials
79 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 5 | 2 | 5 | 13 | — | 25 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | 2 | — | 4 | 2 | 2 | 10 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | — | — | 2 | 2 | — | 4 |
| Leprosy | D007918 | EFO_0001054 | A30 | 1 | 1 | — | 3 | — | 4 |
| Dermatitis herpetiformis | D003874 | — | L13.0 | — | — | — | 1 | 1 | 2 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | 1 | — | 1 |
| Urticaria | D014581 | EFO_0005531 | L50 | — | — | — | 1 | — | 1 |
| Vesiculobullous skin diseases | D012872 | EFO_1000774 | L10-L14 | — | — | — | 1 | — | 1 |
| Leukocytoclastic vasculitis cutaneous | D018366 | EFO_1000974 | D69.0 | — | — | — | 1 | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 1 | 2 | 6 | — | 3 | 11 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | 4 | — | 3 | 10 |
| Fever | D005334 | HP_0001945 | R50.9 | — | — | 1 | — | — | 1 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | — | — | 1 | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | — | — | 1 |
| Benign mucous membrane pemphigoid | D010390 | — | L12.1 | — | 1 | 1 | — | — | 1 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | 1 | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Exanthema | D005076 | HP_0000988 | — | — | 1 | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | — | — | — | 1 |
| Kidney transplantation | D016030 | — | — | 1 | 1 | — | — | — | 1 |
| Pemphigus | D010392 | EFO_1000749 | L10 | — | 1 | — | — | — | 1 |
| Rosacea | D012393 | — | L71 | — | 1 | — | — | — | 1 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | — | — | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 1 | 4 |
| Methemoglobinemia | D008708 | — | D74 | 1 | — | — | — | 1 | 2 |
| Linear iga bullous dermatosis | D062027 | EFO_0009313 | L12.2 | 1 | — | — | — | — | 1 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
| Bacterial infections | D001424 | — | A49 | 1 | — | — | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | 1 | — | — | — | — | 1 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | — | 2 | 2 |
| Prurigo | D011536 | — | L28.2 | — | — | — | — | 1 | 1 |
| Leukemia | D007938 | — | C95 | — | — | — | — | 1 | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | — | — | — | 1 | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | — | — | — | 1 | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | — | — | 1 | 1 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | — | — | — | 1 | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dapsone |
| INN | dapsone |
| Description | Dapsone is a sulfone that is diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacterium leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy. It has a role as an antimalarial, a leprostatic drug, an antiinfective agent and an anti-inflammatory drug. It is a sulfone and a substituted aniline. It is functionally related to a diphenyl sulfone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 80-08-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1043 |
| ChEBI ID | 4325 |
| PubChem CID | 2955 |
| DrugBank | DB00250 |
| UNII ID | 8W5C518302 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
Organism
Plasmodium falciparum 3D7
Gene name
Gene synonyms
NCBI Gene ID
Protein name
hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase
Protein synonyms
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Aczone – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Aczone – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dapsone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,623 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,577 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use